Sonoma Pharmaceuticals has received a new 510(k) clearance from the U.S. Food and Drug Administration for its Microcyn technology-based solution, including specific over-the-counter indications for the face, eyelid and eyelashes. Per this new clearance, Sonoma’s Microcyn wound care solution can be used for OTC management of minor skin abrasions, lacerations and irritations, and intact skin on the face, eyelid and eyelashes. Sonoma believes these are the strongest OTC eye care claims in the HOCl industry. Additionally, the new claim referencing the face will expand how Sonoma can market its OTC dermatology products.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNOA:
- Sonoma Pharmaceuticals, EMC Pharma enter co-marketing collaboration
- Sonoma Pharmaceuticals trading halted, news pending
- Sonoma Pharmaceuticals Stockholders Decide on Key Governance Issues
- Sonoma, MicroSafe announce Australian TGA approval for NanoCyn extended claims
- Sonoma Pharmaceuticals enters distribution agreement for wound care products